Compare MPTI & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPTI | ACIU |
|---|---|---|
| Founded | 1965 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.9M | 288.0M |
| IPO Year | 2022 | 2015 |
| Metric | MPTI | ACIU |
|---|---|---|
| Price | $92.59 | $2.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $71.00 | $10.00 |
| AVG Volume (30 Days) | 56.4K | ★ 246.7K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $54,417,000.00 | N/A |
| Revenue This Year | $11.06 | $706.75 |
| Revenue Next Year | $12.15 | $321.13 |
| P/E Ratio | $135.36 | ★ N/A |
| Revenue Growth | ★ 11.03 | N/A |
| 52 Week Low | $36.38 | $1.60 |
| 52 Week High | $90.69 | $4.00 |
| Indicator | MPTI | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 75.58 | 31.11 |
| Support Level | $60.13 | $2.03 |
| Resistance Level | N/A | $3.13 |
| Average True Range (ATR) | 4.19 | 0.17 |
| MACD | 1.14 | -0.03 |
| Stochastic Oscillator | 91.48 | 3.45 |
M-Tron Industries Inc is an electronic components manufacturer based in the United States. Along with its subsidiaries, the company is engaged in designing, manufacturing, and marketing high-engineered, high-reliability frequency and spectrum control products used to control the frequency or timing of signals in electronic circuits in various applications. The company serves markets in aerospace and defense, space, and avionics sectors. Its product offerings include microwave and millimeter-wave filters, crystal resonators, clock oscillators, voltage-controlled crystal oscillators, low noise amplifiers, couplers, attenuators, and switches, among others. Geographically, it derives maximum revenue from the domestic market, and the rest from Malaysia, Australia, Greece, and other countries.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.